Open the map

Charles River LaboratoriesCRL

CDMO & pharma manufacturing · NYSE · USA

$298.00
Down 0.8% todayClose

Up 50.5% this year and +38.1% since June 26, ahead of the life science sector at +10.7%. Charles River Laboratories supplies 8 mapped companies.

Market cap
$13.8B
This year
+50.5%
1 year
+76.5%
P/E
n/a
P/S
3.5
P/B
4.9

Price vs the life science sector

since Jun 26CRLLife science sector, equal weight
Charles River Laboratories (CRL) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. CRL: +38.1% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+10%+20%+30%+40%Jun 26AugSepOct 8CRL +38.1%Sector +10.7% Charles River Laboratories (CRL) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. CRL: +38.1% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+20%+40%Jun 26AugSepOct 8CRL+38.1%Sector+10.7%

Supply chain

8 customers
SUPPLIERS →→ CUSTOMERSNone mappedPfizer (PFE)PFEPfizer−0.6%Eli Lilly (LLY)LLYEli Lilly−1.6%Bristol Myers Squibb (BMY)BMYBristol Myers Squibb−0.2%Zoetis (ZTS)ZTSZoetis+2.1%Alnylam Pharmaceuticals (ALNY)ALNYAlnylam Pharmaceuti…+0.1%Incyte (INCY)INCYIncyte−0.6%BioMarin Pharmaceutical (BMRN)BMRNBioMarin Pharmaceut…−0.6%Regeneron (REGN)REGNRegeneron−0.3%CRLCharles River L…

Customers 8

Open the full chain →

About Charles River Laboratories

Preclinical work that drug and biotech companies choose not to do in-house: research models, safety testing, laboratory services through development, and support for cell and gene therapy.

Theme exposure

PreclinicalCROOutsourcingPreclinical researchOutsourced development

Products

  • Preclinical models
  • Safety testing
  • Cell & gene therapy services

Competitors

Risks

  • Biotech funding cycles
  • Regulatory changes (animal models)

Same segment: CDMO & pharma manufacturing

Contract development and manufacturing of medicines, the industrial backbone behind the drugs. Segment 4 of 8 in the Medicine, pharma & life science value chain.

IQVIA HoldingsIQV+0.3%West Pharmaceutical ServicesWST−0.9%

Compare CRL

Side by side with the largest companies in the same segment.

CRL vs IQVCRL vs WST

See where Charles River Laboratories sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →